brexucabtagene autoleucel
gilead
['leusm', 'brexu-cel', 'kitepharma']
icymi: the ages of the 76 patients treated with s brexu-cel ranged from 18 years to 81 years (median, 44). #asco23 #celltherapy #leusm read more: 
CGTLive™ delivers quality and relevant information to healthcare professionals on cell, gene, regenerative, and engineered medicines to ultimately improve care.